BioSpace News Archive

I-Mab (the “Company”)(Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced a strategic partnership with Kalbe Genexine Biologics (“KG Bio”),

Immunovia invites you to a teleconference for all stakeholders and media on Wednesday, April 1, 2020 at 16:30 CET.

CHASE Clinical Trial. On September 23, 2019, the Company announced findings from the pre-specified interim review of its ongoing CHASE clinical trial.

The device is designed to restore vision to persons blinded by age-related macular degeneration and retinitis pigmentosa

Clozex Reduces The Anxiety Of A Visit To The Emergency Room Or Urgent Care And Is A Proven And Cost-effective Treatment.

Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson ,

EUA Application Follows Completion of Test Validation with Patient Samples by Physician-Scientists at UC San Diego

Article reviews mechanisms of action (MOA) of medications used in the treatment of patients with narcolepsy and clinical implications

Avive Solutions, Inc, a developer of a next-generation Automated External Defibrillator and innovative cardiac arrest response solutions, was selected to present a study on a novel machine-learning algorithm for arrhythmia classification via a podium presentation at the American College of Cardiology Conference 2020.

Agilent Technologies Inc. (NYSE: A) today introduced the Agilent K6460S Clinical Edition TQ LC/MS system, designed to improve in vitro diagnostic workflows in clinical labs.